There will be two significant Catalysts here that should deliver significant SH Value.
1 The MND Topline Data
2, The FDA granting Orphan Drug Designation
I will then consider the likelihood of a T/O as MT the CEO has disclosed that the current incumbent treatment is under FDA Review , if that MND Treatment has its FDA approval revoked , then the chance of Big Pharma Buying this one very swiftly is High .
@asx11 of all of the ASX Companies I have followed or invested in PAA is the most Undervalued and virtually invisible as the Promotion Historically has been extremely poor , up until November last year the company had not capitalised on any Scientific Progress.. 10 years worth of progress is only now stating to be recognized with any associated value $$$$$
- Forums
- ASX - By Stock
- Ann: Extension Study Begins, Analysis Suggests Survival Benefit
There will be two significant Catalysts here that should deliver...
-
- There are more pages in this discussion • 162 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
18.0¢ |
Change
-0.005(2.70%) |
Mkt cap ! $87.55M |
Open | High | Low | Value | Volume |
18.5¢ | 18.5¢ | 17.8¢ | $111.9K | 621.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 522333 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 8390 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 522333 | 0.175 |
10 | 517592 | 0.170 |
5 | 162060 | 0.165 |
8 | 475304 | 0.160 |
6 | 336734 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 8390 | 1 |
0.185 | 264464 | 3 |
0.190 | 485322 | 7 |
0.195 | 687718 | 12 |
0.200 | 297726 | 10 |
Last trade - 15.33pm 04/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |